Published in Mod Pathol on August 24, 2007
Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol (2012) 1.72
Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. Am J Pathol (2009) 1.48
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia (2008) 1.19
Tissue Microarray: A rapidly evolving diagnostic and research tool. Ann Saudi Med (2009) 1.16
ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol (2013) 1.04
Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol (2015) 0.92
Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol (2013) 0.86
The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility. Int J Gynecol Pathol (2016) 0.78
Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis. Virchows Arch (2015) 0.77
Practical issues in the diagnosis of serous carcinoma of the endometrium. Mod Pathol (2016) 0.75
Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus. Surg Pathol Clin (2012) 0.75
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A (2002) 6.98
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol (2011) 6.34
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med (2009) 5.63
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell (2002) 5.58
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med (2008) 5.19
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol (2011) 4.66
EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell (2003) 4.33
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors. Bioinformatics (2010) 4.02
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med (2011) 3.68
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol (2006) 3.53
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
A large-scale study of the ultrawideband microwave dielectric properties of normal, benign and malignant breast tissues obtained from cancer surgeries. Phys Med Biol (2007) 3.31
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science (2013) 3.25
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet (2010) 3.15
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol (2002) 3.11
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA (2013) 3.06
A DNA microarray survey of gene expression in normal human tissues. Genome Biol (2005) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Determination of stromal signatures in breast carcinoma. PLoS Biol (2005) 2.84
Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A (2006) 2.72
A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol (2008) 2.68
A large-scale study of the ultrawideband microwave dielectric properties of normal breast tissue obtained from reduction surgeries. Phys Med Biol (2007) 2.68
Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol (2011) 2.64
Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol (2003) 2.59
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. Hum Pathol (2009) 2.54
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol (2007) 2.47
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36
Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med (2011) 2.25
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst (2009) 2.17
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res (2006) 2.16
Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol (2012) 2.12
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A (2006) 2.08
Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol (2010) 2.04
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol (2009) 2.04
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res (2009) 2.00
Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr (2009) 1.98
The Stanford Tissue Microarray Database. Nucleic Acids Res (2007) 1.96
Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol (2005) 1.94
TLE1 as a diagnostic immunohistochemical marker for synovial sarcoma emerging from gene expression profiling studies. Am J Surg Pathol (2007) 1.94
Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol (2013) 1.94
3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One (2010) 1.91
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol (2008) 1.90
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res (2004) 1.90
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol (2010) 1.87
Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol (2012) 1.86
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci U S A (2012) 1.86
The fibromatosis signature defines a robust stromal response in breast carcinoma. Lab Invest (2008) 1.85
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. Am J Surg Pathol (2012) 1.83
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Gene expression in the normal adult human kidney assessed by complementary DNA microarray. Mol Biol Cell (2003) 1.79
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res (2011) 1.79
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res (2011) 1.76
Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res (2013) 1.75
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat (2007) 1.75
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab (2003) 1.73